Lin Yu-Fen, Chen Benjamin P, Li Wende, Perko Zoltan, Wang Yi, Testa Mauro, Schneider Robert, Lu Hsaio-Ming, Gerweck Leo E
Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Int J Part Ther. 2018 Winter;4(3):33-39. doi: 10.14338/IJPT-17-00025.1. Epub 2018 Mar 21.
Variations in the radiosensitivity of tumor cells within and between tumors impact tumor response to radiation, including the dose required to achieve permanent local tumor control. The increased expression of DNA-PKcs, a key component of a major DNA damage repair pathway in tumors treated by radiation, suggests that DNA-PKcs-dependent repair is likely a cause of tumor cell radioresistance. This study evaluates the relative biological effect of spread-out Bragg-peak protons in DNA-PKcs-deficient cells and the same cells transfected with a functional DNA-PKcs gene.
A cloned radiation-sensitive DNA-PKcs-deficient tumor line and its DNA-PKcs-transfected resistant counterpart were used in this study. The presence of functional DNA-PKcs was evaluated by DNA-PKcs autophosphorylation. Cells to be proton irradiated or x-irradiated were obtained from the same single cell suspension and dilution series to maximize precision. Cells were concurrently exposed to 6-MV x-rays or mid 137-MeV spread-out Bragg peak protons and cultured for colony formation.
The surviving fraction data were well fit by the linear-quadratic model for each of 8 survival curves. The results suggest that the relative biological effectiveness of mid spread-out Bragg peak protons is approximately 6% higher in DNA-PKcs-mediated resistant tumor cells than in their DNA-PKcs-deficient and radiation-sensitive counterpart.
DNA-PKcs-dependent repair of radiation damage is less capable of repairing mid spread-out Bragg peak proton lesions than photon-induced lesions, suggesting protons may be more efficient at sterilizing DNA-PKcs-expressing cells that are enriched in tumors treated by conventional fractionated dose x-irradiation.
肿瘤内部及不同肿瘤之间的肿瘤细胞放射敏感性存在差异,这会影响肿瘤对放疗的反应,包括实现永久性局部肿瘤控制所需的剂量。DNA-PKcs是放疗治疗肿瘤中主要DNA损伤修复途径的关键组成部分,其表达增加表明依赖DNA-PKcs的修复可能是肿瘤细胞放射抗性的一个原因。本研究评估了扩展Bragg峰质子在DNA-PKcs缺陷细胞以及转染了功能性DNA-PKcs基因的相同细胞中的相对生物学效应。
本研究使用了一个克隆的对辐射敏感的DNA-PKcs缺陷肿瘤细胞系及其转染了DNA-PKcs的抗性对应细胞系。通过DNA-PKcs自身磷酸化评估功能性DNA-PKcs的存在。用于质子照射或X射线照射的细胞来自相同的单细胞悬液和稀释系列,以最大限度提高精度。细胞同时暴露于6兆伏X射线或137兆电子伏特中期扩展Bragg峰质子,并培养用于集落形成。
8条生存曲线中的每一条,其存活分数数据都很好地符合线性二次模型。结果表明,中期扩展Bragg峰质子在DNA-PKcs介导的抗性肿瘤细胞中的相对生物学效应比其DNA-PKcs缺陷且对辐射敏感的对应细胞高约6%。
依赖DNA-PKcs的辐射损伤修复对中期扩展Bragg峰质子损伤的修复能力低于光子诱导的损伤,这表明质子在杀灭表达DNA-PKcs的细胞方面可能更有效,这些细胞在传统分次剂量X射线照射治疗的肿瘤中富集。